Annuaire de la recherche en pneumologie
| Nom du Laboratoire | Inflammation et Fibrogenese pulmonaires |
|---|---|
| N° d'équipe | INSERM 1152-Equipe 2 – Physiopathologie et épidémiologie des maladies respiratoires |
| Nom du directeur du laboratoire | Pretolani Marina |
| Nom du responsable | Pr Bruno Crestani |
| Courriel du responsable | bruno.crestani@aphp.fr |
| Contacts principaux | BRUNO CRESTANI : bruno.crestani@aphp.fr ARNAUD MAILLEUX (chargé de recherche Inserm): arnaud.mailleux@inserm.fr |
| Adresse | Faculté Xavier Bichat, 16 rie Henri Huchard |
| CP | 75018 |
| Ville | Paris |
| Pays | France |
| Téléphone | 01 40 25 68 00 |
| Fax | 01 40 25 88 18 |
| Site internet | http://u1152.e-monsite.com/pages/pages-internes/equipe-3.html |
| Mots clés | fibrose pulmonaire; ARDS; fibroblaste; |
| Résumé | Our aim is to decipher the mechanisms and pathways involved in the development of lung fibrosis, in acute and chronic settings. Our disease models are ARDS, Idiopathic pulmonary fibrosis and connective tissue disease-associated lung fibrosis. We will address different issues which are a potential source of innovation in this field : 1) We will identify and target the transcription factors (TF) which control the profibrotic phenotype of pulmonary fibroblasts in vitro and in vivo; the developmental and mesenchyme-associated TF PRRX1will be our first target. 2) Lung fibrosis is associated with the reactivation of signaling pathways involved in lung development, including the Fibroblast Growth Factor (FGF)/FGFR pathways. We will explore and manipulate in vivo the antifibrotic potential of the FGF/FGFR4 pathway. 3) Lung cancer is a frequent comorbidity in patients with lung fibrosis. We will characterize the molecular pathways controlling lung cancer in patients and determine how the fibrotic environment drives tumor growth in vitro and in vivo. 4) The genes associated with familial pulmonary fibrosis are identified in a minority of patients. We will identify new genetic susceptibility pathways in lung fibrotic disorders, including familial pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. |
| Axe principal | fibrose pulmonaire; SDRA; cancer bronchopulmonaire |
